Results 51 to 60 of about 71,002 (280)

NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression

Nature Communications, 2019
Cancer cells respond differently to inhibitors of Poly (ADP-ribose) polymerase. Here the authors reveal that ovarian cancer cells with higher cellular NADP+ levels are more sensitive to clinically relevant PARP1 inhibitors and show that NADP+ act as an ...
Chunjing Bian, Chao Zhang, Tao Luo, Aditi Vyas, Shih-Hsun Chen, Chao Liu, Muzaffer Ahmad Kassab, Ying Yang, Mei Kong, Xiaochun Yu   +9 more
doaj   +1 more source

Targeted Therapy in Ovarian Cancer

healthbook TIMES. Oncology Hematology, 2021
Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding of OC biology has led to the development of several targeted therapies, including antiangiogenic agents and poly(ADP-ribose) polymerase ...
Marcus Vetter, Alexandra Leary
doaj   +1 more source

Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib [PDF]

, 2018
Upon DNA binding the poly(ADP-ribose) polymerase family of enzymes (PARPs) add multiple ADP-ribose subunits to themselves and other acceptor proteins.
Albert, Ali, Ame, Amit Nathubhai, Audebert, Barkauskaite, Beck, Benhur, Benjamin, Blenn, Boehler, Boulton, Braun, Bridges, Brochu, Bryant, Bryant, Bryant, Calabrese, Chalmers, Chang, Chang, Chang, Chow, Cortes, deMurcia, Ding, Dominic I. James, Donawho, Drean, Dungey, Dungey, Efimova, El-Khamisy, Emma Grant, Erdelyi, Fabbro, Fathers, Feng, Feng, Feng, Fisher, Godon, Gravells, Ha, Helen E. Bryant, Huang, Illuzzi, James, James Neale, Kate M. Smith, Khan, Kim, Le Page, Lee, Lomax, Martin, Medvedeva, Min, Miwa, Morrison, Mueller, Nakadate, Nathubhai, Noel, Okano, Oplustil O'Connor, Ozaki, Polly Gravells, Ray Chaudhuri, Rothkamm, Rulten, Rulten, Saleh-Gohari, Schlicker, Schreiber, Senra, Shall, Shelton, Shirai, Shirai, Slade, Strom, Sugimura, Tripathi, Trucco, Venere, Wang, Wang, Wang, Wieler, Yang, Yeh, Yoshikawa, Zhu   +94 more
core   +2 more sources

Hyperosmotic stress induces PARP1‐mediated HPF1‐dependent mono(ADP‐ribosyl)ation

FEBS Letters, EarlyView.
Sorbitol‐induced hyperosmotic stress rapidly induces reversible mono(ADP‐ribosyl)ation (MARylation) on PARP1 without the signs of genotoxic signaling. We show that PARP1 autoMARylation is HPF1 dependent and forms hydroxylamine‐resistant O‐glycosidic linkages.
Anna Georgina Kopasz, Mihály Mérey, Rebeka Vásárhelyi, Ramóna Pék, Victor Imburchia, László Henn, Adrián Kószó, Nicholas D. Lakin, Ivan Ahel, Sébastien Huet, Ágnes Czibula, Gyula Timinszky   +11 more
wiley   +1 more source

Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens

Nature Communications, 2020
Mutations in the homologous recombination proteins BRCA1 and BRCA2 can sensitize cells to treatment with inhibitors of poly-ADP-ribose polymerase 1 (PARPi), but resistance to the treatment can occur.
Kristen E. Clements, Emily M. Schleicher, Tanay Thakar, Anastasia Hale, Ashna Dhoonmoon, Nathanial J. Tolman, Anchal Sharma, Xinwen Liang, Yuka Imamura Kawasawa, Claudia M. Nicolae, Hong-Gang Wang, Subhajyoti De, George-Lucian Moldovan   +12 more
doaj   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

A guide to poly ADP-ribose polymerase inhibitor (PARPi) toxicity management [PDF]

International Journal of Gynecological Cancer, 2020
Ovarian cancer is the fifth most common cause of cancer-related death in women and is the leading cause of gynecologic-related deaths in the United States.[1 2][1] Only ~40% of patients with ovarian cancer achieve a cure and the 5-year overall survival is ~47%.[1][1] The majority of ...
Shrina Divyesh, Patel, Donyika Ann, Joseph   +1 more
openaire   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Methylation status of Dnmt1 promoter depends on poly(ADP-ribosy)lation [PDF]

, 2007
Research is focused on CpG islands and on the mechanism that poly(ADP-ribosyl)ation uses to defend the unmethylated state of these important DNA sequences which are located in the promoter regions of the housekeeping genes having a role of transcription ...
Zampieri, Michele
core   +1 more source

Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors

Molecular & Cellular Oncology, 2020
Coactivator-associated arginine methyltransferase 1 (CARM1)-expressing high-grade serous ovarian cancers are characterized by poor prognosis and limited therapeutic options.
Sergey Karakashev, Rugang Zhang
doaj   +1 more source